- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02496312
Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated. (ECOCAPTURE)
October 31, 2017 updated by: Institut National de la Santé Et de la Recherche Médicale, France
Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated in Healthy Subjects and Patients With Frontotemporal Dementia. Pilot Phase.
The purpose of this study is to provide relevant quantitative evaluation of apathy close to real life situation by means of a multimodal sensor system integrated.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigators try to measure the amount of goal-directed behaviour and to detect the pattern of apathy.
The main objective of this pilot phase is to select the variables of goal-directed behaviour from the list of metrics providing by the multimodal acquisition system in healthy subjects and patients with frontotemporal dementia.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of Frontotemporal Dementia (FTD) according to diagnostic criteria reported by Rascovsky et al. (2011).
- Understanding of the instructions and capacity to realize the cognitive tasks.
- Capacity to read, to understand and to sign legal document of information
- Capacity for informed consent for research, capacity to sign consent
- MMSE score > 20
- Absence of other cerebral pathology.
- Absence of psychiatric disease interfering with the assessment of the tests
- Absence of excessive psychotropic use
- Access to National Healthcare Insurance
- Accompanied with a caregiver
Exclusion Criteria:
- Excessive psychotropic use
- Incapacity or refusal to realize the experimental tasks
- Subject deprived of freedom by an administrative or court order
- Subject under legal protective measure.
- Incapacity for informed consent for research
- Participation in another biomedical research
- Airway obstruction risk
- Reduction of activity not attributable to another chronic pathological condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ECOCAPTURE
Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
|
Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of each behavior from the ethogram
Time Frame: 45 min
|
[Provided by the video recording and The Observer NOLDUS software]
|
45 min
|
Frequency of each behavior from the ethogram
Time Frame: 45 min
|
[Provided by the video recording and The Observer NOLDUS software]
|
45 min
|
Duration of each behavior from the ethogram
Time Frame: 45 mn
|
[Provided by the video recording and The Observer NOLDUS software]
|
45 mn
|
Number of different behaviors
Time Frame: 45 mn
|
[Provided by the video recording and The Observer NOLDUS software]
|
45 mn
|
Activity classes
Time Frame: 45 mn
|
[Provided by the MOVE MOVISENS sensor] lying, sitting, ...
|
45 mn
|
Body positions
Time Frame: 45 mn
|
[Provided by the MOVE MOVISENS sensor] lying left, ...
|
45 mn
|
Energy expenditure
Time Frame: 45 mn
|
[Provided by the MOVE MOVISENS sensor] kcal.
|
45 mn
|
MET
Time Frame: 45 mn
|
[Provided by the MOVE MOVISENS sensor] The Metabolic Equivalent of Task.
MET level.
|
45 mn
|
Steps
Time Frame: 45 mn
|
[Provided by the MOVE MOVISENS sensor] Counting steps.
|
45 mn
|
Activity intensity
Time Frame: 45 mn
|
[Provided by the MOVE MOVISENS sensor] g.
|
45 mn
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Richard LEVY, PhD, MD, INSERM UMR_S 1127, ICM
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Robert PH, Clairet S, Benoit M, Koutaich J, Bertogliati C, Tible O, Caci H, Borg M, Brocker P, Bedoucha P. The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry. 2002 Dec;17(12):1099-105. doi: 10.1002/gps.755.
- Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):243-54. doi: 10.1176/jnp.3.3.243.
- Muller U, Czymmek J, Thone-Otto A, Von Cramon DY. Reduced daytime activity in patients with acquired brain damage and apathy: a study with ambulatory actigraphy. Brain Inj. 2006 Feb;20(2):157-60. doi: 10.1080/02699050500443467.
- Pasquier F, Lebert F, Lavenu I, Guillaume B. The clinical picture of frontotemporal dementia: diagnosis and follow-up. Dement Geriatr Cogn Disord. 1999;10 Suppl 1:10-4. doi: 10.1159/000051206.
- Mayo NE, Fellows LK, Scott SC, Cameron J, Wood-Dauphinee S. A longitudinal view of apathy and its impact after stroke. Stroke. 2009 Oct;40(10):3299-307. doi: 10.1161/STROKEAHA.109.554410. Epub 2009 Aug 27.
- Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, Bradshaw JL, White OB. Negative symptoms: A review of schizophrenia, melancholic depression and Parkinson's disease. Brain Res Bull. 2006 Oct 16;70(4-6):312-21. doi: 10.1016/j.brainresbull.2006.06.007. Epub 2006 Jul 5.
- Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis. 1994 Apr;182(4):235-9. doi: 10.1097/00005053-199404000-00008.
- Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L. The Lille Apathy Rating Scale: validation of a caregiver-based version. Mov Disord. 2008 Apr 30;23(6):845-9. doi: 10.1002/mds.21968.
- Lane-Brown AT, Tate RL. Apathy after acquired brain impairment: a systematic review of non-pharmacological interventions. Neuropsychol Rehabil. 2009 Aug;19(4):481-516. doi: 10.1080/09602010902949207.
- Czernecki V, Pillon B, Houeto JL, Welter ML, Mesnage V, Agid Y, Dubois B. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease? J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):775-9. doi: 10.1136/jnnp.2003.033258.
- Le Jeune F, Drapier D, Bourguignon A, Peron J, Mesbah H, Drapier S, Sauleau P, Haegelen C, Travers D, Garin E, Malbert CH, Millet B, Verin M. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology. 2009 Nov 24;73(21):1746-51. doi: 10.1212/WNL.0b013e3181c34b34.
- Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006 Jul;16(7):916-28. doi: 10.1093/cercor/bhj043. Epub 2005 Oct 5.
- Levy R, Czernecki V. Apathy and the basal ganglia. J Neurol. 2006 Dec;253 Suppl 7:VII54-61. doi: 10.1007/s00415-006-7012-5.
- Brown RG, Pluck G. Negative symptoms: the 'pathology' of motivation and goal-directed behaviour. Trends Neurosci. 2000 Sep;23(9):412-7. doi: 10.1016/s0166-2236(00)01626-x.
- Funkiewiez A, Bertoux M, de Souza LC, Levy R, Dubois B. The SEA (Social cognition and Emotional Assessment): a clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration. Neuropsychology. 2012 Jan;26(1):81-90. doi: 10.1037/a0025318. Epub 2011 Sep 5.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 10, 2015
Primary Completion (Actual)
October 2, 2015
Study Completion (Actual)
October 2, 2015
Study Registration Dates
First Submitted
July 2, 2015
First Submitted That Met QC Criteria
July 13, 2015
First Posted (Estimate)
July 14, 2015
Study Record Updates
Last Update Posted (Actual)
November 6, 2017
Last Update Submitted That Met QC Criteria
October 31, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Neurodegenerative Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Language Disorders
- Communication Disorders
- Speech Disorders
- Frontotemporal Lobar Degeneration
- Aphasia
- Dementia
- Frontotemporal Dementia
- Aphasia, Primary Progressive
- Pick Disease of the Brain
Other Study ID Numbers
- C15-14
- 2015-A0087-42 (Registry Identifier: RCB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frontotemporal Dementia
-
University of California, San FranciscoForest LaboratoriesCompletedSemantic Dementia | Frontal Lobe Dementia | Frontotemporal Lobe DementiaUnited States
-
Mayo ClinicRecruitingPrimary Progressive Aphasia | Behavioral Variant of Frontotemporal Dementia | Frontotemporal Dementia, Behavioral VariantUnited States
-
University of PennsylvaniaEnrolling by invitationFrontotemporal Degeneration | Frontotemporal Dementia | Frontotemporal Dementia, Behavioral Variant | FTDUnited States
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedTauopathies | Frontotemporal Dementia (FTD) | Frontotemporal Lobar Degeneration (FTLD)United States
-
Massachusetts General HospitalNational Institutes of Health (NIH); National Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Caregiver Stress Syndrome | Caregiver Burnout | Dementia, Mild | Dementia Moderate | Dementia Severe | Dementia FrontotemporalUnited States
-
Lawson Health Research InstituteRecruitingLewy Body Dementia (LBD) | Alzheimer Dementia (AD) | Dementia, FrontotemporalCanada
-
BiogenCompletedFrontotemporal Dementia | Behavioral Variant Frontotemporal DementiaUnited States
-
Vesper Biotechnologies ApSRecruitingDementia, FrontotemporalNetherlands
-
HealthPartners InstituteTerminatedFrontotemporal Dementia, Behavioral VariantUnited States
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS); National Institute...CompletedFamilial Frontotemporal DementiaUnited States, Canada
Clinical Trials on Evaluation of Apathy Close to Real Life Situation
-
University Hospital, Strasbourg, FranceRecruitingHealth Related Quality of Life | Veno-arterial Extra-Corporeal Membrane OxygenationFrance
-
St. John Health System, OklahomaUnknownMalnutrition | GastrostomyUnited States
-
University Hospital, LimogesRecruitingCytomegalovirus Infections | Hematopoietic Stem Cell Transplantation | Antivirals | Antiviral Drug ResistanceFrance
-
Rennes University HospitalRecruiting
-
Wills EyeMerck Sharp & Dohme LLCCompleted
-
Marmara UniversityRecruitingFamilial Mediterranean Fever | Autonomic DysfunctionTurkey
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingStage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic CarcinomaUnited States
-
Centre Antoine LacassagneUniversity of Lyon; University of Firenze and Siena, Napoli, ItalyRecruiting